Thermo Fisher Scientific (TMO) : Forte Capital Adv reduced its stake in Thermo Fisher Scientific by 4.07% during the most recent quarter end. The investment management company now holds a total of 9,418 shares of Thermo Fisher Scientific which is valued at $1,431,819 after selling 400 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Thermo Fisher Scientific makes up approximately 0.55% of Forte Capital Adv’s portfolio.
Other Hedge Funds, Including , Premier Asset Managment reduced its stake in TMO by selling 1,500 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 82,795 shares of TMO which is valued at $12,587,324. Thermo Fisher Scientific makes up approx 3.21% of Premier Asset Managment’s portfolio.Kelman-lazarov boosted its stake in TMO in the latest quarter, The investment management firm added 185 additional shares and now holds a total of 570 shares of Thermo Fisher Scientific which is valued at $90,693. Thermo Fisher Scientific makes up approx 0.05% of Kelman-lazarov’s portfolio. Simplex Trading sold out all of its stake in TMO during the most recent quarter. The investment firm sold 381 shares of TMO which is valued $60,278.Telemus Capital boosted its stake in TMO in the latest quarter, The investment management firm added 1,625 additional shares and now holds a total of 26,242 shares of Thermo Fisher Scientific which is valued at $4,153,584. Thermo Fisher Scientific makes up approx 0.46% of Telemus Capital’s portfolio.
Thermo Fisher Scientific closed down -4.21 points or -2.65% at $154.9 with 26,97,528 shares getting traded on Tuesday. Post opening the session at $156, the shares hit an intraday low of $153.79 and an intraday high of $156.585 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.